ATE500328T1 - Vaskuläre adhesionsmoleküle und modulierung ihrer funktion - Google Patents

Vaskuläre adhesionsmoleküle und modulierung ihrer funktion

Info

Publication number
ATE500328T1
ATE500328T1 AT00920497T AT00920497T ATE500328T1 AT E500328 T1 ATE500328 T1 AT E500328T1 AT 00920497 T AT00920497 T AT 00920497T AT 00920497 T AT00920497 T AT 00920497T AT E500328 T1 ATE500328 T1 AT E500328T1
Authority
AT
Austria
Prior art keywords
adhesion molecules
modulation
function
vascular adhesion
cram
Prior art date
Application number
AT00920497T
Other languages
English (en)
Inventor
Beat Imhof
Michel Aurrand-Lions
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of ATE500328T1 publication Critical patent/ATE500328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT00920497T 1999-03-11 2000-03-13 Vaskuläre adhesionsmoleküle und modulierung ihrer funktion ATE500328T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (1)

Publication Number Publication Date
ATE500328T1 true ATE500328T1 (de) 2011-03-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920497T ATE500328T1 (de) 1999-03-11 2000-03-13 Vaskuläre adhesionsmoleküle und modulierung ihrer funktion

Country Status (23)

Country Link
US (3) US7393651B2 (de)
EP (2) EP2292761A1 (de)
JP (2) JP4836329B2 (de)
CN (2) CN100469878C (de)
AT (1) ATE500328T1 (de)
AU (1) AU782139B2 (de)
BR (1) BR0008915A (de)
CA (1) CA2362896C (de)
CZ (1) CZ303128B6 (de)
DE (1) DE60045681D1 (de)
EE (1) EE05497B1 (de)
ES (1) ES2361905T3 (de)
HK (1) HK1044169A1 (de)
HU (1) HU229376B1 (de)
IL (1) IL145310A0 (de)
IS (1) IS2819B (de)
MX (1) MXPA01009110A (de)
NO (1) NO333085B1 (de)
NZ (1) NZ514091A (de)
PL (1) PL207994B1 (de)
RU (1) RU2244748C2 (de)
WO (1) WO2000053749A2 (de)
ZA (1) ZA200107283B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (de) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
UA99591C2 (ru) 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
WO2008038127A2 (en) 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
PL2097455T3 (pl) 2006-11-02 2015-04-30 Genentech Inc Humanizowane przeciwciała przeciw czynnikowi D
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
RU2612388C2 (ru) * 2007-08-06 2017-03-09 Ноксон Фарма Аг Связывающие sdf-1 нуклеиновые кислоты и их применение
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
CA2944712A1 (en) 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
JP2001524814A (ja) * 1997-03-14 2001-12-04 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド ２８種類のヒト分泌タンパク質
WO1998042739A2 (en) * 1997-03-21 1998-10-01 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CA2296809A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins identified from brain tissues
US20030082541A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (de) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR und relatierte V Domäne zur Herstellung eines Arzneimittels zur Vorbeugung oder Behandlung von HSV-1, HSV-2 und BHV Infektionen
EP1141285A2 (de) * 1998-12-16 2001-10-10 Genentech, Inc. Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
CZ303128B6 (cs) * 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (de) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs

Also Published As

Publication number Publication date
ES2361905T3 (es) 2011-06-24
HUP0200606A3 (en) 2004-11-29
CN100469878C (zh) 2009-03-18
US20080274970A1 (en) 2008-11-06
AU782139B2 (en) 2005-07-07
WO2000053749A2 (en) 2000-09-14
CN1637019A (zh) 2005-07-13
RU2244748C2 (ru) 2005-01-20
NO20014417D0 (no) 2001-09-11
EE05497B1 (et) 2011-12-15
NZ514091A (en) 2004-01-30
HU229376B1 (en) 2013-11-28
EP1163337B1 (de) 2011-03-02
IS2819B (is) 2012-12-15
JP2002537837A (ja) 2002-11-12
IS6072A (is) 2001-09-10
US20100267649A1 (en) 2010-10-21
EP1163337A2 (de) 2001-12-19
EE200100472A (et) 2002-12-16
US7670826B2 (en) 2010-03-02
CA2362896A1 (en) 2000-09-14
CA2362896C (en) 2012-07-31
BR0008915A (pt) 2002-04-09
US20050266426A1 (en) 2005-12-01
CZ20013267A3 (cs) 2002-02-13
DE60045681D1 (de) 2011-04-14
JP2010233572A (ja) 2010-10-21
PL207994B1 (pl) 2011-02-28
NO333085B1 (no) 2013-02-25
CN1355843A (zh) 2002-06-26
JP4836329B2 (ja) 2011-12-14
AU4105100A (en) 2000-09-28
IL145310A0 (en) 2003-01-12
CZ303128B6 (cs) 2012-04-18
US7393651B2 (en) 2008-07-01
MXPA01009110A (es) 2002-08-20
HK1044169A1 (en) 2002-10-11
HUP0200606A2 (en) 2002-06-29
WO2000053749A3 (en) 2000-12-14
US8143056B2 (en) 2012-03-27
NO20014417L (no) 2001-11-12
EP2292761A1 (de) 2011-03-09
ZA200107283B (en) 2002-12-24
PL350417A1 (en) 2002-12-16

Similar Documents

Publication Publication Date Title
ATE500328T1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
PT1132403E (pt) Peptidos inibidores de tgf g beta1
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
ATE369385T1 (de) Neuer metabotropischer glutamat-rezeptor vom menschen
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE155485T1 (de) Bpc-peptide, ihre herstellung und verwendung
BR9007115A (pt) Novo trombolitico
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
EP0870036A4 (de) Synthetische säugetier alpha-n-aectylglukosaminidase und dafür kodierende genetische sequenzen
ATE317021T1 (de) Antisense modulierung von lfa-3
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
AU9743698A (en) Allelic variant of human stat3
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties